Key result
Bivalirudin achieved therapeutic aPTT sooner than argatroban or lepirudin (8.5 vs 14 and 24 hours, respectively; p=0.124) in patients with heparin-induced thrombocytopenia.
Why the study?
Do direct thrombin inhibitors (bivalirudin, argatroban, lepirudin) differ in time to therapeutic aPTT and clinical outcomes in patients with heparin-induced thrombocytopenia?
Population
42 hospitalized patients with heparin-induced thrombocytopenia or presumed HIT treated with a direct…
Comparison
Bivalirudin (n=24) vs Argatroban (n=13) and lepirudin (n=5)
Design
Cohort
Authors
Loading...
Similar outcomes among direct thrombin inhibitors in HIT support current practice; observational data leave comparative efficacy open for randomized trials.
Observational (n=42)
No
Do direct thrombin inhibitors (bivalirudin, argatroban, lepirudin) differ in time to therapeutic aPTT and clinical outcomes in patients with heparin-induced thrombocytopenia?
Absolute Event Rate: 8.5% vs 14%
p-value: p=0.124
In patients with HIT, bivalirudin, argatroban, and lepirudin showed similar efficacy and clinical outcomes, though bivalirudin may offer cost advantages.
Dang et al. (2006) conducted an observational in Heparin-induced thrombocytopenia (HIT) or presumed HIT (n=42). Bivalirudin vs. Argatroban and lepirudin was evaluated on Time to reach the desired goal for activated partial thromboplastin time (aPTT) (p=0.124). Bivalirudin achieved therapeutic aPTT sooner than argatroban or lepirudin (8.5 vs 14 and 24 hours, respectively; p=0.124) in patients with heparin-induced thrombocytopenia.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: